Recent News and Articles on the Keywords: announced + hepatitis + cure Related to the article below (Last Update: 8/5/2008)
Vertex on the Verge of Victory Motley Fool - Today, Vertex's main rival in hepatitis C treatments, Schering-Plough (NYSE: SGP), announced excellent new phase 2 data for its competing compound, ...VRTX - JNJ
ViRexx Announces Approvals Of Rights Offering Medical News Today (press release), UK - Its platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and ...REX
Why has it taken this long to tackle Hepatitis? Daily Monitor, Uganda - Aug 3, 2008 Government, in conjunction with the World Health Organisation, last week announced a Shs10 billion programme to help fight the spread of the disease and ...
ViRexx Announces Approvals of Rights Offering FOXBusiness - Aug 1, 2008 Its platform technologies include product candidates for the treatment of Hepatitis B, Hepatitis C, avian influenza viral infections, biodefence and ...REX - OTC:CMTX
Chronic Hepatitis B: Current and Future Treatment Options - A Rivkina, S Rybalov - Pharmacotherapy, 2002 - PPI ... A new pegylated interferon recently was approved for treatment of hepatitis C. In
this agent, a polyethylene glycol molecule is attached to interferon. ...
Treatment of chronic hepatitis C virus infection - SD Malnick - The Annals of Pharmacotherapy, 2000 - Harvey Whitney Books ... Treatment of Chronic Hepatitis C Virus Infection ... OBJECTIVE : To review the literature
on the treatment of chronic hepatitis C virus (HCV) infection. ...
First clinical data on RNAi - J Whelan - Drug Discovery Today, 2005 - Elsevier ... It has also announced a collaboration with the University of ... for RNAi is likely to
be hepatitis C. Sirna's developmental siRNA treatment for hepatitis...
A ?C?change for hepatitis treatment - J Clough - Drug Discovery Today, 2002 - Elsevier ... Recently, data from a clinical trial that is thought to be the first to use a
monoclonal antibody in the treatment of hepatitis C has been announced by XTL ...
Thymosin alpha1. SciClone Pharmaceuticals. A Billich - Curr Opin Investig Drugs, 2002 - ncbi.nlm.nih.gov ... for the treatment of HBV and hepatitis C virus ... In March 2000, approval for treatment
of HBV infection ... In September 2000, SciClone announced that approval had ...
Daily Consensus Interferon Shows Better Efficacy Against HCV Than Pegylated Interferon - M Kerr - Accessed at www. medscape. com/viewarticle. 547344_print, …, 2006 - medscape.com ... Combined Therapy (DIRECT) trial were announced here this ... randomized trial shows that
daily treatment with consensus ... to 25% in patients with hepatitis C virus ...
Payments announced for patients infected with hepatitis C - C Dyer - BMJ: British Medical Journal, 2004 - pubmedcentral.nih.gov ... 29 August 2003, when the government first announced that it ... scheme will cover anyone
infected with hepatitis C through NHS treatment before September ...
[CITATION] Payments announced for patients infected with hepatitis C PDF Abridged - British Medical Journal - Br Med Assoc
[CITATION]Hepatitis C Protease Inhibitor Shows" Dramatic" Antiviral Effects M Kerr
Source: Google Scholar
Hepatitis C Cure Announced By VCU Researcher
The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher said yesterday.
Mitchell Shiffman, M.D., professor in the VCU School of Medicine, and chief of hepatology and medical director of the Liver Transplant Program at the Virginia Commonwealth University Medical Center, is one of the lead investigators in the study, which was presented at the 38th annual Digestive Disease Week conference in Washington, D.C. VCU was among about 40 sites worldwide studying pegylated interferon alfa-2a, manufactured by Roche Inc.
Nearly all -- 99 percent - of patients with hepatitis C who were treated successfully with peginterferon alone, or in combination with ribavirin, had no detectable virus up to seven years later. Researchers say this data validates the use of the word "cure" when describing hepatitis C treatment as successful treatment is defined as having undetectable hepatitis C virus in the blood six months following treatment.
Article continues below and (thank you)
"We at VCU are encouraged by this data because it is rare in the treatment of life-threatening viral diseases that we can tell patients they may be cured," Shiffman said. "In hepatitis C today, we are able to help some patients achieve an outcome that effectively enables them to put their disease behind them."
The results are based on a long-term follow-up study designed to determine if the virus re-emerges in patients who have achieved treatment success. The study reviewed 997 patients, either mono-infected with chronic HCV or co-infected HCV and HIV, who achieved a sustained viral response (SVR) following treatment with either Pegasys (peginterferon alfa-2a) monotherapy or combination therapy with Pegasys and ribavirin.
After successful treatment, researchers monitored serum levels of HCV once a year for an average of 4.1 years (range 0.4 to 7 years). Of the 997 patients, 989 maintained undetectable levels of HCV. The remaining eight patients tested positive for HCV at an average of two years following treatment completion. The study found that these eight patients exhibited no consistency in age, gender or HCV genotype, and it has not yet been determined if these patients experienced a relapse or if they were re-infected with HCV.
Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention, an estimated 4.1 million Americans have been infected with hepatitis C, and 3.2 million are chronically infected. The number of new infections per year declined from an average of 240,000 in the 1980s to about 26,000 in 2004, the latest year for which statistics are available. The CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.
###
The Digestive Disease Week conference is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 19-24, 2007, at the Washington Convention Center, Washington, D.C. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit http://www.ddw.org/.
About VCU and the VCU Medical Center: Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 30,000 students in nearly 200 certificate and degree programs in the arts, sciences and humanities. Sixty-three of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see http://www.vcu.edu/.
Pollutants, food ingredients, solvents may all cause harm, researchers say.
By Alan Mozes HealthDay Reporter
MONDAY, May 14 (HealthDay News) -- A detailed analysis of hundreds of completed breast cancer studies has linked disease development with environmental exposure to more than 200 chemical compounds.
The finding is part of an effort to build a free, online breast cancer database for researchers and the public.
Described as "the most comprehensive of its kind," the database will highlight growing concern about environmental carcinogens such as pollutants, food contaminants, and organic solvents. The scope of the project will also extend to work that explores risk-related lifestyle factors such as diet, levels of physical activity, smoking/drinking habits and body mass.
"This compilation is a great effort, because it summarizes all the evidence and gives us hints of what to look for next," explained researcher Leslie Bernstein, a professor of preventive medicine with the Keck School of Medicine at the University of Southern California in Los Angeles.
The results are outlined in a supplement to the May 14th online issue of Cancer. The database is already accessible at either www.silentspring.org/sciencereview or www.komen.org/environment.
According to the American Cancer Society (ACS), carcinogens are defined as agents that instigate abnormal cell division or harmful changes in the structure of a cell's DNA. They include chemicals, radiation, or infectious agents, among other things.
The ACS also notes that with the exception of skin cancer, breast cancer is the most common cancer among American women. This year, almost 179,000 women in the United States will be diagnosed with the disease, and about 40,000 will die.
The International Agency of Research on Cancer has already classified 90 or so compounds as human carcinogens, according to the ACS. But Bernstein's team said that most of the chemicals to which people are routinely exposed have not undergone any testing for carcinogenic risk. An estimated 80,000 chemicals are registered in the United States for commercial use, according to the researchers.
For more than two years, Bernstein worked alongside colleagues from Harvard University, the Roswell Park Cancer Institute, and the Silent Spring Institute to amass and sort through approximately 900 national and international breast cancer studies focused on carcinogens.
The team honed in on 460 human breast cancer studies, of which more than 150 looked at specific environmental carcinogens among breast cancer patients. Most of those studies were conducted in the 1990s.
The remaining studies involved animal or laboratory research. The researchers pointed out that animal studies are valid references, because all known human carcinogens have also triggered tumors in animal subjects.
In the animal studies alone, evidence surfaced that linked 216 chemicals to the onset of breast tumors. These included 36 industrial chemicals, 6 chlorinated solvents, 18 products of combustion, 10 pesticides, 18 dyes, four type of radiation, 47 pharmaceuticals, and 17 hormones.
Of these compounds, the researchers isolated 73 that can be found in either human food or consumer products.
They noted, for example, the lingering hazards associated with polychlorinated biphenyls (or PCBs), which were typically used in the production of electrical equipment until federally banned in 1979. PCBs continue to pose a risk via contaminated rivers, fish, and pre-existing building construction, the researchers warned.
In addition, the authors categorized 35 compounds as carcinogenic air pollutants, including polycyclic aromatic hydrocarbons (or PAHs), which are byproducts of combustion.
The team also drew attention to another group of 25 organic compounds, including dioxins, which are produced by waste incineration and manufacturing. These carcinogenic chemicals are present in many American workplaces and place more than 5,000 women at an increased risk for breast cancer, the researchers said. These include women working in machine shops, dry cleaners, hairdressers, glass manufacturers, and aircraft maintenance facilities, all of which use harmful organic solvents.
Furthermore, among the identified carcinogens, 29 are produced in large amounts -- upwards of one million pounds or more per year.
The database project did not set strict guidelines as to how to limit exposure to carcinogens. But the authors said they encouraged research and government oversight into the problem. They advised that people do try and limit their exposure to PCB-contaminated fish, gasoline-generated air pollution, chlorinated tap water, non-stick coated cookware, and detergents containing fluorescent whiteners.
Just how carcinogenic, in terms of breast cancer risk, are these and other compounds on the list? The jury is still out on that question, Bernstein said.
"Women are terribly concerned about environmental causes of breast cancer," she said. "But it's really very difficult to study. Often the only way we've been able to look at some of these things is during occupational exposures or accidents -- what we usually call disasters."
"So, this work is a very useful tool for those of us who want to try to understand what we've missed in breast cancer. Now, it's up to us to do something with all this information," Bernstein said.
Janet Gray, a professor of psychology and the director of the program in science, technology and society at Vassar College in Poughkeepsie, N.Y., called the new database "an enormous contribution."
"Its greatest value is just the sheer comprehensive nature of the work, which allows both the public and researchers to have access to huge amounts of information in one place," she said. "I think this effort will really move us forward."
Known and Probable Carcinogens
Including Industrial Processes, Occupational Exposures, Infectious Agents, Chemicals, and Radiation)
What Is a Carcinogen?
Cancer is caused by abnormalities in a cell’s DNA (its genetic "blueprint"). These may be inherited from parents, or they may be caused by outside exposures to the body such as chemicals, radiation, or even infectious agents.
Substances that can cause changes that can lead to cancer are called carcinogens. Some carcinogens do not act on DNA directly, but lead to cancer in other ways, such as causing cells to divide at a faster rate, which could increase the chances that DNA changes will occur.
Carcinogens do not cause cancer in every case, all the time. Substances classified as carcinogens may have different levels of cancer-causing potential. Some may cause cancer only after prolonged, high levels of exposure. And for any particular person, the risk of developing cancer depends on many factors, including the length and intensity of exposure to the carcinogen and the person’s genetic makeup.
How Do We Determine if Something Is a Carcinogen? Scientists get much of their data about whether something might cause cancer from laboratory (cell culture and animal) studies. Although it isn’t possible to predict with certainty which substances will cause cancer in humans based on animal studies alone, virtually all known human carcinogens that have been adequately tested produce cancer in lab animals. In many cases, carcinogens are first found to cause cancer in lab animals and are later found to cause cancer in people. Because there are far too many substances (natural and manmade) to test each one in lab animals, scientists use knowledge about chemical structure, other types of lab tests, and information about the extent of human exposure to select chemicals for testing.
Most studies of potential carcinogens expose the lab animals to doses that are higher than common human exposures. This is so that cancer risk can be detected in relatively small groups of animals. For most carcinogens, it is assumed that those that cause cancer at larger doses in animals will also cause cancer in people. Although it isn’t always possible to know the relationship between exposure dose and risk, it is reasonable for public health purposes to assume that lowering human exposure will reduce risk.
Another important way to identify carcinogens is through epidemiologic studies, which look at human populations to determine which factors might be linked to cancer. While these studies also provide useful information, they also have their limitations. Humans do not live in a controlled environment. People are exposed to numerous substances at any one time, including those they encounter at work, school, or home; in the food they eat; and the air they breathe. And it is usually many years (often decades) between exposure to a carcinogen and the development of cancer. Therefore, it can be very hard to single out any particular exposure as having a definite link to cancer.
By combining data from both types of studies, scientists are able to make an educated assessment of a substance’s cancer-causing ability. When the available evidence is compelling but not felt to be conclusive, the substance may be considered to be a probable carcinogen.
How Are Carcinogens Classified?
International Agency for Research on Cancer (IARC)
The most widely used system for classifying carcinogens comes from the IARC, which is part if the World Health Organization (WHO). In the past 30 years, the IARC has evaluated the cancer-causing potential of about 900 likely candidates, placing them into one of the following groups:
Group 1: Carcinogenic to humans
Group 2A: Probably carcinogenic to humans
Group 2B: Possibly carcinogenic to humans
Group 3: Unclassifiable as to carcinogenicity in humans
Group 4: Probably not carcinogenic to humans
Perhaps not surprisingly, most of the agents are of probable, possible, or unknown risk. Only about 90 are classified as "carcinogenic to humans."
National Toxicology Program (NTP)
In the United States, the NTP releases the Report on Carcinogens about every 2 years. The NTP is formed from parts of several different government agencies, including the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).
The Report on Carcinogens (RoC) identifies 2 groups of agents:
"Known to be human carcinogens"
"Reasonably anticipated to be human carcinogens"
Unlike the IARC’s list, the RoC does not list substances that have been studied and found not to be carcinogens. Below are the lists of known and probable human carcinogens from both groups.
Known Human Carcinogens
International Agency for Research on Cancer (IARC) "Carcinogenic to Humans" (Group 1)
Agents and Groups of Agents
Aflatoxins (naturally occurring mixtures of)
4-Aminobiphenyl
Arsenic and arsenic compounds (Note: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)
Estrogens, nonsteroidal (Note: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)
Estrogens, steroidal (Note: This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group)
Ethylene oxide
Etoposide in combination with cisplatin and bleomycin
Formaldehyde
Gallium arsenide
Gamma radiation
Helicobacter pylori (infection with)
Hepatitis B virus (chronic infection with)
Hepatitis C virus (chronic infection with)
Herbal remedies containing plant species of the genus Aristolochia
Human immunodeficiency virus type 1 (infection with)
Human papillomavirus type 16
Human papillomavirus type 18
Human T-cell lymphotropic virus type I
Melphalan
8-Methoxypsoralen (Methoxsalen) plus ultraviolet A radiation
MOPP and other combined chemotherapy including alkylating agents
Mustard gas (Sulfur mustard)
2-Naphthylamine
Neutrons
Nickel compounds
Opisthorchis viverrini (infection with)
Oral contraceptives, combined (Note: There is also conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium)
Oral contraceptives, sequential
Phosphorus-32, as phosphate
Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols
Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation (exposure during childhood)
Radionuclides, alpha-particle-emitting, internally deposited (Note: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents)
Radionuclides, beta-particle-emitting, internally deposited (Note: Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents)
Radium-224 and its decay products
Radium-226 and its decay products
Radium-228 and its decay products
Radon-222 and its decay products
Schistosoma haematobium (infection with)
Silica, crystalline (inhaled in the form of quartz or cristobalite from occupational sources)
Solar radiation
Talc containing asbestiform fibers
Tamoxifen (Note: There is also conclusive evidence that this agent (tamoxifen) reduces the risk of contralateral breast cancer)
2,3,7,8-Tetrachlorodibenzo-para-dioxin
Thiotepa
Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide
Treosulfan
Vinyl chloride
X- and Gamma radiation
Mixtures
Alcoholic beverages
Analgesic mixtures containing phenacetin
Areca nut
Betel quid with tobacco
Betel quid without tobacco
Coal-tar pitches
Coal-tars
Mineral oils, untreated and mildly treated
Salted fish (Chinese-style)
Shale-oils
Soots
Tobacco products, oral tobacco products
Wood dust
Exposure Circumstances
Aluminum production
Arsenic in drinking water
Auramine, manufacture of
Boot and shoe manufacture and repair
Coal gasification
Coke production
Furniture and cabinet making
Hematite mining (underground) with exposure to radon
